As mentioned previously, preclinical studies using xenografts of HER2-amplified tumor have shown no benefit with monotherapy with anti-HER2 antibodies (pertuzumab) or TKI (lapatinib), while combination therapy with pertuzumab and lapatinib showed anti-tumor activity [11]. This evidence concerns the gene ERBB2 and neoplasm.